These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9919340)

  • 1. Topoisomerase-I inhibitors in gynaecologic tumours.
    Verschraegen CF; Kudelka AP; Kavanagh JJ
    Ann Acad Med Singap; 1998 Sep; 27(5):683-7. PubMed ID: 9919340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase-I inhibitors in gynecologic tumors.
    Haluska P; Rubin E; Verschraegen CF
    Hematol Oncol Clin North Am; 1999 Feb; 13(1):43-61, vii-viii. PubMed ID: 10080069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the treatment of cervical and uterine carcinoma: focus on topotecan.
    Fiorica JV
    Oncologist; 2002; 7 Suppl 5():36-45. PubMed ID: 12324632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
    Wethington SL; Wright JD; Herzog TJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):819-31. PubMed ID: 18471053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
    Terauchi F
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():175-8. PubMed ID: 15535228
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ
    Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan for the treatment of cervical cancer.
    Verschraegen CF
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan in cervical cancer.
    Kavanagh JJ; Verschraegen CF; Kudelka AP
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):94-8. PubMed ID: 9726099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
    Hwang JH; Lim MC; Seo SS; Park SY; Kang S
    Jpn J Clin Oncol; 2011 May; 41(5):624-9. PubMed ID: 21355002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of chemotherapy in gynecologic cancer.
    Tropé C; Kristensen G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-1-S15-22. PubMed ID: 9346216
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
    Jabłońska E; Chłosta M; Pawlega J
    Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
    Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
    Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
    Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
    Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecological cancers.
    Boente MP; Schilder R; Ozols RF
    Cancer Chemother Biol Response Modif; 1999; 18():418-34. PubMed ID: 10800496
    [No Abstract]   [Full Text] [Related]  

  • 19. Irinotecan in epithelial ovarian cancer.
    Gershenson DM
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.
    Meng LH; Liao ZY; Pommier Y
    Curr Top Med Chem; 2003; 3(3):305-20. PubMed ID: 12570765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.